The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens

Cancer

Volumn 78, Issue 2, 1996, Pages 350-356

  Epstein, Jonathan I ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

adenocarcinoma of the prostate; core needle biopsy specimens of the prostate; Gleason grade; high molecular weight cytokeratin

Indexed keywords

CYTOKERATIN; PROSTATE SPECIFIC ANTIGEN;

CANCER GRADING; CONFERENCE PAPER; IMMUNOHISTOCHEMISTRY; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY;

ADENOCARCINOMA; BIOPSY, NEEDLE; CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; MOLECULAR WEIGHT; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030055159     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960715)78:2<350::AID-CNCR26>3.0.CO;2-U     Document Type: Conference Paper

References (39)

1. Epstein JI, Walsh PC, CarMichael M, Brendler CB. Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271:368-74.
2. Troxel DB, Sabella JD. Problem areas in pathology practice, Uncovered by a review of malpractice claims. Am J Surg Pathol 1994; 18:821-31.
3. Epstein JI. Interpretation of prostate biopsies. 2nd edition. Philadelphia: Lippincott-Raven, 1996.
4. Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 1995; 26:223-9.
5. Totten RS, Heinemann NW, Hudson PB, Sproul EE, Stout AP. Microscopic differential diagnosis of latent carcinoma of the prostate. Arch Pathol Lab Med 1953; 55:131-41.
6. Srigley JR. Small-acinar patterns in the prostate gland with emphasis on atypical adenomatous hyperplasia and small-acinar carcinoma. Semin Diagn Pathol 1988; 5:254-72.
7. Kovi J. Microscopic differential diagnosis of small acinar adenocarcinoma of prostate. Path Ann 1985; 20(Pt 1):157-96.
8. Gleason DF. Atypical hyperplasia, benign hyperplasia, and well-differentiated adenocarcinoma of the prostate. Am J Surg Pathol 1985; 93:53-67.
9. Mostofi FK, Sesterhenn IA, Davis CJ. Prostatic carcinoma: problems in the interpretation of prostatic biopsies. Hum Pathol 1992; 23:223-41.
10. Kelemen PR, Buschmann RJ, Weisz-Carrington P. Nucleolar prominence as a diagnostic variable in prostatic carcinoma. Cancer 1990; 65:1017-20.
11. Epstein JI, Armas OA. Atypical basal cell hyperplasia of the prostate. Am J Surg Pathol 1992; 16:1205-14.
12. Epstein JI, Fynheer J. Acidic mucin in the prostate: can it differentiate adenosis from adenocarcinoma? Hum Pathol 1992; 23:1321-5.
13. Bastacky SI, Walsh PC, Epstein JI. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Am J Surg Pathol 1993; 17:336-41.
14. McIntyre TL, Frazini DA. The presence of benign prostatic glands in perineural spaces. J Urol 1986; 135:507-9.
15. Gaudin PB, Epstein JI. Adenosis of the prostate: histologic features in transurethral resection specimens. Am J Surg Pathol 1994; 18:863-70.
16. Gaudin PB, Epstein JI. Adenosis of the prostate: histologic features in needle biopsy specimens. Am J Surg Pathol 1995; 19:737-47.
17. Murphy WM, Ramsey J, Soloway MS. A better nuclear fixative for diagnostic bladder and prostate biopsies. J Urol Pathol 1993; 1:79-87.
18. Oppenheimer JR, Kahane H, Epstein JI. Granulomatous prostatitis on needle biopsy - characterization and clinical correlation of 124 cases. Med Pathol 1996; 9:80A.
19. Stillwell TJ, Engen DE, Farrow GM. The clinical spectrum of granulomatous prostatitis: a report of 200 cases. J Urol 1987; 138:320-3.
20. Gleason DF. The Veterans Administration Cooperative Urological Research Group. Histologie grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: the Prostate. Philadelphia: Lea and Febiger, 1977:171-97.
21. Steinberg D, Sauvageot J, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy: Gleason grade in academic and community settings. Med Pathol 1996; 9:83A.
22. Spires SE, Cibull ML, Wood DP Jr, Miller S, Spires SM, Banks ER. Gleason histologic grading in prostatic carcinoma. Correlation of 18-guage core biopsy with prostatectomy. Arch Pathol Lab Med 1994; 118:705-8.
23. Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994; 18:796-803.
24. Albertson PC, Fryback DG, Storer BE, Kolon RF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 74:626-31.
25. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996; 20:286-92.
26. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologie differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990; 66:1225-33.
27. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150:110-4.
28. Kojima M, Troncoso P, Babaian RJ. Use of prostate-specific antigen and tumor volume in predicting needle biopsy grading error. Urology 1995; 45:807-12.
29. Huland H, Hammerer P, Henke RP, Huland E. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination, PSA, and the results of six systemic biopsies. J Urol 1996; 155:1344-7.
30. Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA. Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer 1991; 75:530-8.
31. Ackerman DA, Barry JM, Wicklund RA, Olson N, Lowe B. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 1993; 150:1845-50.
32. Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989; 13:389-96.
33. O'Malley FP, Grignon DJ, Shum DT. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol 1990; 417:191-6.
34. Shah IA, Schlageter MO, Stinnett P, Lechago J. Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate. Mod Pathol 1991; 4:220-4.
35. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 1985; 45:3663-7.
36. Wojno KJ, Epstein JI. The utility of basal cell specific anticytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer: a review of 228 cases. Am J Surg Pathol 1995; 19:251-60.
37. Okada H, Tsubura A, Okamura A, Senzaki H, Naka Y, Komatz Y, et al. Keratin profiles in normal/hyperplastic prostates and prostate carcinoma. Virchows Arch A Pathol Anat Histopathol 1992; 421:157-61.
38. Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res 1987; 47:281-6.
39. Kahane H, Sharp JW, Shuman GB, Dasilva G, Epstein JI. Utilization of high molecular weight cytokeratin on prostate biopsies in an independent laboratory, Urology 1995; 45: 981-6.